市場調查報告書

生物製藥的全球市場:市場規模、佔有率、預測、機會分析 - 各藥品級、治療領域、流通管道、地區

Biologics Market: by Drug Class, by Therapeutic Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 931959
出版日期 內容資訊 英文 317 Pages
商品交期: 2-3個工作天內
價格
生物製藥的全球市場:市場規模、佔有率、預測、機會分析 - 各藥品級、治療領域、流通管道、地區 Biologics Market: by Drug Class, by Therapeutic Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年04月03日內容資訊: 英文 317 Pages
簡介

所謂生物製藥,是從生物生產的物質應用製作的藥,疫苗,血液,血液成分,過敏原,體細胞,基因治療藥,組織等有廣泛的產品。許多生物製藥採用基因重組技術製造。近幾年,由於法規機關承認複數的生物製藥,製藥企業發售各種創新的生物製藥。預期新產品迅速的核准和上市是這個市場的主要推動因素。

本報告提供全球生物製藥市場調查,市場概要,各藥品級、治療領域、流通管道、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各藥品類別
    • 市場片段:各治療領域
    • 市場片段:各流通管道
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 市場成長要素
    • 市場阻礙因素
    • 市場機會
  • 生物製藥 & 生物相似藥概要
  • 影響分析
  • 專利期間分析
  • 開發平台分析
  • 法規方案
  • 償付方案
  • 產品的認證和上市
  • 聯盟、收購
  • 市場趨勢
  • PEST分析
  • 流行病學

第4章 全球生物製藥市場:各藥品類別

  • 簡介
  • 單株抗體
  • 疫苗
  • 基因重組胰島素製劑
  • 人體生長荷爾蒙
  • 凝血因子
  • 融合蛋白室
  • 促血紅細胞生長素
  • 干擾素
  • 基因重組酵素
  • 細胞聚落刺激因子
  • 細胞療法
  • 遺傳基因療法
  • 寡核甘酸
  • 其他

第5章 全球生物製藥市場:各治療領域

  • 簡介
  • 癌症、腫瘤
  • 代謝疾病
  • 自體免疫疾病、免疫疾病
  • 眼科疾病
  • 發炎性腸道疾病(IBD)
  • 呼吸疾病
  • 神經疾病
  • 肌肉骨骼疾病
  • 心血管疾病
  • 感染疾病
  • 其他

第6章 全球生物製藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球生物製藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • Bristol-Myers Squibb Company (BMS)
    • Merck & Co., Inc.
    • Roche AG
    • Merck KGaA
    • AstraZeneca Plc
    • Regeneron Pharmaceuticals, Inc
    • Novartis International AG
    • Pfizer, Inc.
    • Amgen, Inc.
    • AbbVie, Inc.
    • Sanofi S.A.
    • Eli Lilly & Company
    • Novo Nordisk A/S
    • Johnson & Johnson
    • GlaxoSmithKline Plc
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen S.A.
    • Allergan Plc.

第9章 章節

  • 參考資料
  • 調查手法
  • 關於Coherent Market Insights
目錄

Biological products include wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for the treatment of genetic disorders. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. Moreover, in 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Market Dynamics

In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologics market. For instance, in 2017, Amgen Inc. received the U.S. Food and Drug Administration (FDA) for its Blincyto (Blinatumomab) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

Furthermore, in 2017, Janssen Biotech, Inc. received the U.S FDA approval for Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma.

However, high cost of biologics for the treatment of diseases such as rheumatoid arthritis, cancer, multiple sclerosis, psoriasis, and other diseases is expected to hamper biologics market growth over the forecast period. For instance, according to the data published in NCBI in 2018, the cost of biologics for treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases can range from US$ 10,000 to US$ 30,000 per year in the U.S. and can exceed US$ 500,000 per year for the most expensive biologics.

Furthermore, it is more difficult to manufacture biologics than chemical drugs, as they are extremely sensitive due to its very complex molecules.

Key features of the study:

This report provides in-depth analysis of the global biologics market, market size (US$ Bn), and compound annual growth rate (CAGR (%) for the forecast period, 2020-2027, considering 2019 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global biologics market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies

Key players covered as a part of this study include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global biologics market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Global Biologics Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Biologics Market, by Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Cell Therapy
  • Gene Therapy
  • Oligonucleotides
  • Others
  • Global Biologics Market, By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • Global Biologics Market, by Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Biologics Market, by Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • By Drug Class:
  • Monoclonal Antibody
  • Vaccine
  • Recombinant Insulin
  • Human Growth Hormone
  • Blood Factor
  • Fusion Protein
  • Erythropoietin
  • Recombinant Enzyme
  • Interferon
  • Colony-stimulating Factor
  • Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
  • By Therapeutic Application:
  • Oncology
  • Metabolic Disorders
  • Autoimmune/Immunologic Diseases
  • Ophthalmic Diseases
  • Inflammatory Bowel Diseases (IBDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Musculoskeletal Disorders (MSDs)
  • Cardiovascular Diseases (CVDs)
  • Infectious Diseases
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • Bristol-Myers Squibb Company (BMS) *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Merck & Co., Inc.
  • Roche AG
  • Merck KGaA
  • AstraZeneca Plc
  • Regeneron Pharmaceuticals, Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Eli Lilly & Company
  • Novo Nordisk A/S
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen S.A.
  • Allergan Plc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapeutic Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Biologics & Biosimilars Overview
  • Impact Analysis
  • Patent Expiry Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Product Approval/Launch
  • Collaboration-Acquisition
  • Market Trends
  • PEST Analysis
  • Epidemiology

4. Global Biologics Market, By Drug Class, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Recombinant Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Blood Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Fusion Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Erythropoietin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Recombinant Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Colony-stimulating Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Oligonucleotides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Others (Peptide, Botulinum Toxin, and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

5. Global Biologics Market, By Therapeutic Application, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Metabolic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Autoimmune/Immunologic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Ophthalmic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Inflammatory Bowel Diseases (IBDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Respiratory Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Musculoskeletal Disorders (MSDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Cardiovascular Diseases (CVDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

6. Global Biologics Market, By Distribution Channel, 2019 - 2027, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Billion)

7. Global Biologics Market, By Region, 2019 - 2027 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Billion)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Billion)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Bristol-Myers Squibb Company (BMS)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Regeneron Pharmaceuticals, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly & Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Ipsen S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact